TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04333160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTA-004
Description: Patients will undergo a single intra-articular injection of JTA-004 into the knee joint

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will undergo a single intra-articular injection of placebo into the knee joint
Study: NCT03063008

Intervention type: DEVICE
Group type: OTHER
Intervention: PEEK
Description: Procedure/Surgery:~TLIF fusion with common PEEK cages.

Intervention type: DEVICE
Group type: OTHER
Intervention: TiPEEK
Description: Procedure/Surgery:~TLIF fusion with titanium coated PEEK cages.
Study: NCT02046044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Study: NCT04999059

Intervention type: OTHER
Intervention: Safety and Efficacy Assessments
Description: Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.
Study: NCT02205073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo RD + AVP SD
Description: Placebo (matching to study drug) repeat doses + intranasal AVP single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo RD + Placebo SD
Description: Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG7314 RD + AVP SD
Description: RG7314 repeat doses + intranasal AVP single dose
Study: NCT02902523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread® tablet 300mg
Description: Single dose administration(PO) in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUG116 tablet 245mg
Description: Single dose administration(PO) in the fasted state
Study: NCT03511027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SME + Karie Device
Description: For the duration of the study, participants will use the Karie device to promote medication adherence. The Karie device prompts users to take their medication in the right amount at the right time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SME only
Description: At discharge, participants will be provided with self-medication education.
Study: NCT02213159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT03401463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traning seminar
Description: There will be provided 30 min training seminar on the function of endotracheal cuff and cuff pressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traning seminar
Description: There will be provided 30 min training seminar on the function of endotracheal cuff and cuff pressure.
Study: NCT02045446

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance chemotherapy
Description: Maintenance chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Description: Maintenance chemotherapy
Study: NCT01988181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BVM-UF biofeedback
Description: The Fresenius 5008 uses an ultrasound and temperature monitor incorporated into the machine to detect ultrasonic velocity and temperature changes to derive the total protein concentration, which is a sum of total plasma proteins and hemoglobin. The relative blood volume is calculated at by dividing the initial concentration of total protein by the total protein concentration at any given time, multiplied by 100. The HD software is based on the critical blood volume entered at the beginning of the dialysis session for each individual patient. The UF rate is adjusted based on the changes in the relative blood volume to the patient's critical relative blood volume.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)
Description: For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)
Description: For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
Study: NCT04143373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: warm saline irrigation
Description: The objective of this research was to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C and 37 ± 1 ° C for control and experimental sides, respectively.
Study: NCT03244306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
Description: Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt
Study: NCT04479787

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: Utilization of BURSTDR stimulation
Study: NCT00118209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: IV or CIVI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: IV or CIVI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: IV or CIVI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: CIVI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: IV
Study: NCT02672748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garden
Description: Two years of financial and technical home gardening support for new gardeners
Study: NCT03564977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted CAR-T cells
Description: MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
Study: NCT02196025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
Study: NCT00200720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Atkins diet (low carbohydrate diet)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet (high carbohydrate diet)
Study: NCT02045095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN7243
Description: Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN7243
Description: Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN7243
Description: Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN7243
Description: Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN7243
Description: Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN7243
Description: Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN7243
Description: Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).
Study: NCT03516422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULTRASOUND DEBRIDEMENT
Description: Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: STANDARD CARE GROUP
Description: The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
Study: NCT02255227

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: one dose for arm 1 and 2 doses for arm 2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: one dose for arm 1 and 2 doses for arm 2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23
Description: one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumo 23
Description: one dose
Study: NCT02134717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy with bronchoalveolar lavage
Description: Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venipunctures
Description: Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
Study: NCT04182841

Intervention type: DEVICE
Group type: OTHER
Intervention: RheOx
Description: RheOX is a CE-marked device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
Study: NCT03930602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Participants will receive BMS-986165.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Participants will receive BMS-986165.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Participants will receive fluvoxamine.
Study: NCT01632891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate
Description: Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Participants received one 600 mg tablet of efavirenz orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Participants received one 600 mg tablet of efavirenz orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Description: Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Description: Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
Study: NCT02129075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given SC or ID

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Description: Given SC or ID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poly ICLC
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Flt3 Ligand
Description: Given SC
Study: NCT02555995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT scan (as yet unnamed)
Description: OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
Study: NCT04033003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group ANC
Description: Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
Study: NCT04479787

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management
Description: Assessing type of CMM, location and frequency.
Study: NCT02398266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)
Description: Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress
Study: NCT03294603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: 1mg \[14C\]-CC-220 will be administered as a single dose

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [14C]
Description: Single dose of \[14C\]-CC-220 will contain approximately 1.4 μCi of radioactivity
Study: NCT01457495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib (Infanrix-hexa™)
Description: 3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-IPV/Hib (Infanrix-IPV/Hib™)
Description: 3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
Study: NCT04243811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: LLLT with dental needle for local anesthesia during dental treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical anesthesia
Description: topical anesthesia with dental needle for local anesthesia during dental treatment
Study: NCT02223520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin and Chlorhexidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment and placebo cloths
Study: NCT03194594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride, dexamethasone, and combination of two drugs
Description: After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride, dexamethasone, and combination of two drugs
Description: After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
Study: NCT01457495

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBV (Engerix™-B)
Description: 3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8
Study: NCT01959646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aged Garlic Extract Supplementation Group
Description: Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard for Groups
Description: To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard for Groups
Description: To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to consume three (3) placebo capsules with food twice a day.
Study: NCT03693768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health coaching
Description: Health coaching
Study: NCT03377946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotics
Description: the probiotics group was taking probiotics 4 packets a day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotics
Description: the probiotics group was taking probiotics 4 packets a day

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the placebo group was taking placebo 4 packets a day

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the placebo group was taking placebo 4 packets a day
Study: NCT02825069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early introduction of solid foods
Description: Early introduction of solid foods